Edition:
United Kingdom

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

82.78USD
14 Jun 2019
Change (% chg)

$-0.12 (-0.14%)
Prev Close
$82.90
Open
$82.59
Day's High
$83.37
Day's Low
$82.46
Volume
2,891,079
Avg. Vol
3,213,252
52-wk High
$84.26
52-wk Low
$59.81

Latest Key Developments (Source: Significant Developments)

Amgen Sues HHS On Rule Requiring Drug Prices In TV Ads
Friday, 14 Jun 2019 

June 14 (Reuters) - Amgen Inc ::AMGEN INC - ON JUNE 14, AMGEN, MERCK, LILLY, AND ASSOCIATION OF NATIONAL ADVERTISERS, FILED SUIT IN U.S. DISTRICT COURT FOR THE DISTRICT OF COLUMBIA.AMGEN - LAWSUIT SEEKS TO PREVENT U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES' MAY 10 RULE REQUIRING TV ADVERTISEMENTS TO STATE LIST PRICE OF DRUGS.  Full Article

Imv Inc Reports Results From Mid-Stage Trial Testing Its Experimental Lymphoma Treatment
Wednesday, 12 Jun 2019 

June 12 (Reuters) - Imv Inc ::NEW PHASE 2 CLINICAL TRIAL RESULTS CONTINUE TO DEMONSTRATE POTENTIAL CLINICAL BENEFIT OF IMV’S DPX-SURVIVAC IN COMBINATION WITH MERCK’S KEYTRUDA IN PATIENTS WITH DLBCL.IMV INC - COMPLETE RADIOLOGIC RESPONSES LINKED TO T CELL ACTIVITY OBSERVED IN TWO OF FIRST SIX EVALUABLE PATIENTS.IMV - AT FIRST "ON TREATMENT" ASSESSMENT, FIVE OF FIRST SIX PATIENTS DEMONSTRATED CLINICAL BENEFIT, INCLUDING FOUR PATIENTS WITH TUMOR REGRESSIONS.IMV INC - TREATMENT COMBINATION APPEARS TO BE WELL-TOLERATED WITH ONLY 2 SERIOUS ADVERSE EVENTS RELATED TO TREATMENT.  Full Article

Agilent Companion Diagnostic Gains Expanded FDA Approval In Head And Neck Squamous Cell Carcinoma
Tuesday, 11 Jun 2019 

June 11 (Reuters) - Agilent Technologies Inc ::AGILENT COMPANION DIAGNOSTIC GAINS EXPANDED FDA APPROVAL IN HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC).AGILENT TECHNOLOGIES INC - AGILENT COMPANION DIAGNOSTIC GAINS EXPANDED FDA APPROVAL IN HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC).AGILENT TECHNOLOGIES INC - PD-L1 IHC 22C3 PHARMDX CAN NOW BE USED AS AN AID TO IDENTIFY HNSCC PATIENTS FOR TREATMENT WITH KEYTRUDA(PEMBROLIZUMAB).AGILENT TECHNOLOGIES INC - PD-L1 IHC 22C3 PHARMDX CAN NOW BE USED AS AN AID TO IDENTIFY HNSCC PATIENTS FOR TREATMENT WITH KEYTRUDA.  Full Article

FDA Approves Merck's Zerbaxa For Adults With Hospital-Acquired And Ventilator-Associated Pneumonia
Monday, 3 Jun 2019 

June 3 (Reuters) - Merck & Co Inc ::FDA APPROVES MERCK’S ZERBAXA® (CEFTOLOZANE AND TAZOBACTAM) 3G DOSE FOR THE TREATMENT OF ADULTS WITH HOSPITAL-ACQUIRED AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP).MERCK & CO INC - APPROVAL BASED ON RESULTS OF PHASE 3 TRIAL EVALUATING CRITICALLY ILL PATIENTS WITH PNEUMONIA.  Full Article

FDA Approves New Treatment For Hospital-Acquired And Ventilator-Associated Bacterial Pneumonia
Monday, 3 Jun 2019 

June 3 (Reuters) - U.S. Food and Drug Administration::FDA APPROVES NEW TREATMENT FOR HOSPITAL-ACQUIRED AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA.FDA - APPROVED NEW INDICATION FOR ZERBAXA FOR TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA.FDA - GRANTED APPROVAL OF ZERBAXA FOR TREATMENT OF HABP/VABP TO MERCK & CO INC.  Full Article

Bergenbio Presents New Preliminary Clinical In Phase II Trial With Bemcentinib And Keytruda
Sunday, 2 Jun 2019 

June 2 (Reuters) - Bergenbio ASA ::BERGENBIO PRESENTS NEW PRELIMINARY CLINICAL AND BIOMARKER DATA SHOWING DURABLE RESPONSE & MEDIAN SURVIVAL RATES IN PHASE II TRIAL WITH BEMCENTINIB AND KEYTRUDA IN PTS WITH ADVANCED NSCLC AT ASCO 2019.BERGENBIO- PROMISING CLINICAL ACTIVITY CONTINUES TO BE SEEN, PARTICULARLY IN PATIENTS WITH AXL POSITIVE TUMOURS INCLUDING THOSE WITH LOW OR NO PD-L1 EXPRESSION.  Full Article

Merck Says Phase 3 Study Of Keytruda Monotherapy In Triple-Negative Breast Cancer Did Not Meet Primary Endpoint Of Superior Overall Survival
Monday, 20 May 2019 

May 20 (Reuters) - Merck & Co Inc ::MERCK PROVIDES UPDATE ON PHASE 3 KEYNOTE-119 STUDY OF KEYTRUDA® (PEMBROLIZUMAB) MONOTHERAPY IN PREVIOUSLY-TREATED PATIENTS WITH METASTATIC TRIPLE-NEGATIVE BREAST CANCER.MERCK PROVIDES UPDATE ON PHASE 3 KEYNOTE-119 STUDY OF KEYTRUDA® (PEMBROLIZUMAB) MONOTHERAPY IN PREVIOUSLY-TREATED PATIENTS WITH METASTATIC TRIPLE-NEGATIVE BREAST CANCER.MERCK & CO INC - PHASE 3 KEYNOTE-119 STUDY OF KEYTRUDA(® MONOTHERAPY DID NOT MEET ITS PRE-SPECIFIED PRIMARY ENDPOINT OF SUPERIOR OVERALL SURVIVAL.MERCK & CO INC - OTHER ENDPOINTS WERE NOT FORMALLY TESTED PER STUDY PROTOCOL BECAUSE PRIMARY ENDPOINT OF OS WAS NOT MET.MERCK & CO INC - SAFETY PROFILE OF KEYTRUDA IN THIS TRIAL WAS CONSISTENT WITH THAT OBSERVED IN PREVIOUSLY REPORTED STUDIES.MERCK & CO INC - NO NEW SAFETY CONCERNS WERE IDENTIFIED IN STUDY.  Full Article

CPPIB Acquires Partial Royalty Interest In Keytruda From LifeArc
Monday, 20 May 2019 

May 19 (Reuters) - Canada Pension Plan Investment Board : :CPPIB ACQUIRES PARTIAL ROYALTY INTEREST IN KEYTRUDA® (PEMBROLIZUMAB) FROM LIFEARC.CANADA PENSION PLAN INVESTMENT BOARD'S UNIT ACQUIRED PORTION OF LIFEARC'S ROYALTY INTERESTS ON WORLDWIDE SALES OF KEYTRUDA FOR ABOUT $1.3 BILLION.  Full Article

Merck & Co Executive Says "Bolt-On" Deals More Appetizing: Conf. Call
Tuesday, 30 Apr 2019 

April 30 (Reuters) - Merck & Co Inc ::MERCK & CO INC EXECUTIVE SAYS "BOLT-ON" DEALS MORE APPETIZING: CONF. CALL.  Full Article

FDA Approves Merck's Keytruda In Combination With Inlyta As First-Line Treatment For Advanced Renal Cell Carcinoma
Monday, 22 Apr 2019 

April 22 (Reuters) - Merck & Co Inc ::FDA APPROVES MERCK’S KEYTRUDA® (PEMBROLIZUMAB) IN COMBINATION WITH INLYTA® (AXITINIB) AS FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC).MERCK - FDA APPROVES KEYTRUDA (PEMBROLIZUMAB) IN COMBINATION WITH INLYTA AS FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED RENAL CELL CARCINOMA.  Full Article

UPDATE 2-WHO panel decides not to declare international Ebola emergency

* Critics disappointed, say emergency status is justified (Adds statement from head of Wellcome Trust)